SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling -- Ignore unavailable to you. Want to Upgrade?

To: Bocor who wrote (2906)6/26/2001 2:12:02 PM
From: Bocor  Respond to of 6873
 
biz.yahoo.com

Is Xanelim safe enough for patients to take every week for the rest of their lives? That was one of the important questions left unanswered at Thursday's meeting. Genentech and Xoma discussed only partial results today, which means that additional findings, including important details about safety results, still need to be analyzed before a complete picture of the drug can be reviewed.



To: Bocor who wrote (2906)6/27/2001 1:08:43 AM
From: Michail Shadkin  Respond to of 6873
 
Bocor - Re: XOMA

I am very partial to XOMA
I had a huge long position from 6.50 and sold at 10.50 way too early in late april.

I been following them closely, but not ready to start a short yet.
They have broken the multi-year resistance today.

I will watch next few days for a solid entry

Michail


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News